Terconazole Suppliers & Bulk Manufacturers
Available Forms: Cream / Vaginal suppository
Available Strengths: 0.4%, 0.8%, 80 mg, 120 mg
Reference Brands: Terazol (USA)
Category:
Anti-fungal
Terconazole is available in Cream / Vaginal suppository
and strengths such as 0.4%, 0.8%, 80 mg, 120 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Terconazole is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Terconazole can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Terconazole is a broad-spectrum antifungal medication used primarily for the treatment of vulvovaginal candidiasis (vaginal yeast infections). It is available in topical forms such as creams and suppositories and works by disrupting the synthesis of essential lipids in fungal cell membranes, leading to inhibition of fungal growth and cell death.
Compared to other azole antifungals, terconazole has a relatively broad spectrum of activity and has been shown to be effective against multiple Candida species. It is particularly useful as a first-line treatment for acute infections and as a prophylactic option for individuals who suffer from recurrent or chronic vulvovaginal candidiasis. In addition to its activity against vaginal yeast infections, terconazole has demonstrated effectiveness against certain dermatomycoses in preclinical studies. Its targeted mechanism and broad antifungal activity make it a reliable choice for managing fungal infections of the vaginal and cutaneous regions.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing